Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials

JAMA Internal Medicine

Volumn 177, Issue 4, 2017, Pages 554-560

  Wallac, Joshua D ^a   Sullivan, Patrick G ^a   Trepanowski, John F ^a   Sainani, Kristin L ^a   Steyerberg, Ewout W ^b   Ioannidis, John P A ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DATA BASE; DATA EXTRACTION; EFFECT SIZE; HEALTH CARE SURVEY; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCOPUS; UNCERTAINTY; DIAGNOSIS RELATED GROUP; EVIDENCE BASED MEDICINE; INTENTION TO TREAT ANALYSIS; PROCEDURES; PUBLISHING; STANDARDS; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; DIAGNOSIS-RELATED GROUPS; EVIDENCE-BASED MEDICINE; HUMANS; INTENTION TO TREAT ANALYSIS; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85018193823     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.9125     Document Type: Article

References (36)

1. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4): 301-304.
2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
3. Sun X, Briel M, Busse JW, et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: Systematic review. BMJ. 2011;342:d1569.
4. Hernández AV, Boersma E, Murray GD, Habbema JD, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: Are most of them misleading?. Am Heart J. 2006;151(2):257-264.
5. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: Reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-2194.
6. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355(9209): 1064-1069.
7. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Stat Med. 2002;21 (19):2917-2930.
8. Kasenda B, Schandelmaier S, Sun X, et al; DISCO Study Group. Subgroup analyses in randomised controlled trials: Cohort study on trial protocols and journal publications. BMJ. 2014;349:g4539.
9. Sun X, Briel M, Busse JW, et al. Credibility of claims of subgroup effects in randomised controlled trials: Systematic review. BMJ. 2012;344:e1553. doi:10.1136/bmj.e1553
10. Rothwell PM. Treating individuals, 2: Subgroup analysis in randomised controlled trials: Importance, indications, and interpretation. Lancet. 2005;365(9454):176-186.
11. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116(1): 78-84.
12. Sainani K. Misleading comparisons: The fallacy of comparing statistical significance. PM&R. 2010;2 (6):559-562.
13. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.
14. Iqbal SA, Wallach JD, KhouryMJ, Schully SD, Ioannidis JP. Reproducible research practices and transparency across the biomedical literature. PLoS Biol. 2016;14(1):e1002333.
15. Ioannidis JP, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014;383 (9912):166-175.
16. Sun X, Briel M, Busse JW, et al. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): A study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. Trials. 2009;10:101.
17. Girerd N, Rabilloud M, Pibarot P, Mathieu P, Roy P. Quantification of treatment effect modification on both an additive and multiplicative scale. PLoS One. 2016;11(4):e0153010.
18. VanderWeele TJ. On the distinction between interaction and effect modification [published corrections appear in Epidemiology. 2011;22(5):752 and 2010;21(1):162]. Epidemiology. 2009;20(6): 863-871.
19. VanderWeele TJ, Robins JM. Four types of effect modification: A classification based on directed acyclic graphs. Epidemiology. 2007;18(5): 561-568.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45 (pt A):139-145.
21. Altman DG, Bland JM. Interaction revisited: The difference between two estimates. BMJ. 2003; 326(7382):219.
22. Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: A randomized prospective trial. Cancer. 2007;110 (5):1130-1138.
23. Kim F, Olsufka M, LongstrethWT Jr, et al. Pilot randomized clinical trial of prehospital induction of mild hypothermia in out-of-hospital cardiac arrest patients with a rapid infusion of 4°C normal saline. Circulation. 2007;115(24):3064-3070.
24. Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med. 2007;357(24):2431-2440.
25. Pfisterer M, Buser P, Rickli H, et al; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-392.
26. Hunter BR, O'Donnell DP, Allgood KL, Seupaul RA. No benefit to prehospital initiation of therapeutic hypothermia in out-of-hospital cardiac arrest: A systematic review and meta-analysis. Acad Emerg Med. 2014;21(4):355-364.
27. Huang FY, Huang BT, Wang PJ, et al. The efficacy and safety of prehospital therapeutic hypothermia in patients with out-of-hospital cardiac arrest: A systematic review and meta-analysis. Resuscitation. 2015;96:170-179.
28. Kim F, Nichol G, Maynard C, et al. Effect of prehospital induction of mild hypothermia on survival and neurological status among adults with cardiac arrest: A randomized clinical trial. JAMA. 2014;311(1):45-52.
29. Castrén M, Nordberg P, Svensson L, et al. Intra-arrest transnasal evaporative cooling: A randomized, prehospital, multicenter study (PRINCE: Pre-ROSC Intranasal Cooling Effectiveness). Circulation. 2010;122(7):729-736.
30. Corwin HL, Gettinger A, Fabian TC, et al; EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357(10):965-976.
31. Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: A randomized trial. JAMA. 2007;297(19):2092-2102.
32. Löwenberg B, Ossenkoppele GJ, van PuttenW, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acutemyeloid leukemia [published correction appears in N Engl J Med. 2010;362(12):1155]. N Engl J Med. 2009;361 (13):1235-1248.
33. Corwin HL, Gettinger A, Pearl RG, et al; EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA. 2002;288 (22):2827-2835.
34. Pittas AG, Das SK, Hajduk CL, et al. A low-glycemic load diet facilitates greater weight loss in overweight adults with high insulin secretion but not in overweight adults with low insulin secretion in the CALERIE Trial. Diabetes Care. 2005; 28(12):2939-2941.
35. Ebrahim S, Sohani ZN, Montoya L, et al. Reanalyses of randomized clinical trial data. JAMA. 2014;312(10):1024-1032.
36. Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012;41(2):514-520.